PDE5A and pulmonary arterial hypertension: The diagnosis of PAH was prevalent in 41 patients (53%), of which, on the day of right heart catheterization, 20 patients (49%) were treated with an ERA, 30 patients (73%) with a PDE-5 inhibitor and 13 patients (32%) with a prostacyclin derivative.